Axa S.A. Argenx Se Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Argenx Se stock. As of the latest transaction made, Axa S.A. holds 33,574 shares of ARGX stock, worth $21 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

33,574

Previous 36,372 7.69%

Holding current value

$21 Million

Previous $15.6 Million 16.41%

% of portfolio

0.06%

Previous 0.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $1.21 Million - $1.54 Million	-2,798 Reduced 7.69%	33,574 $18.2 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $7,120 - $9,031	20 Added 0.06%	36,372 $15.6 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $2.4 Million - $2.78 Million	-6,721 Reduced 15.6%	36,352 $14.3 Million
Q4 2023 Jul 16, 2024	BUY	$338.91 - $506.01 $2.28 Million - $3.4 Million	6,721 Added 18.49%	43,073 $16.4 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $416,181 - $621,380	-1,228 Reduced 2.77%	43,073 $16.4 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $9.82 Million - $14.6 Million	26,582 Added 150.02%	44,301 $21.8 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $87,514 - $102,686	243 Added 1.39%	17,719 $6.91 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $15.6 Million - $18.9 Million	-46,708 Reduced 72.77%	17,476 $6.51 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $73,224 - $86,094	-214 Reduced 0.33%	64,184 $24.3 Million
Q3 2022 Feb 14, 2023	SELL	$343.2 - $395.75 $6.2 Million - $7.15 Million	-18,079 Reduced 21.92%	64,398 $22.7 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $6.2 Million - $7.15 Million	-18,079 Reduced 21.92%	64,398 $22.7 Million
Q2 2022 Feb 14, 2023	SELL	$269.58 - $378.88 $1.75 Million - $2.46 Million	-6,506 Reduced 7.31%	82,477 $31.2 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $1.75 Million - $2.46 Million	-6,506 Reduced 7.31%	82,477 $31.2 Million
Q1 2022 Feb 14, 2023	BUY	$254.45 - $351.06 $6.26 Million - $8.63 Million	24,585 Added 38.18%	88,983 $28.1 Million
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $166,919 - $230,295	-656 Reduced 0.73%	88,983 $28.1 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $13.4 Million - $17.4 Million	49,401 Added 122.77%	89,639 $31.4 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $436,895 - $519,208	1,481 Added 3.82%	40,238 $12.2 Million
Q2 2021 Aug 13, 2021	SELL	$257.11 - $319.92 $756,931 - $941,844	-2,944 Reduced 7.06%	38,757 $11.7 Million
Q1 2021 May 14, 2021	SELL	$268.3 - $380.31 $995,929 - $1.41 Million	-3,712 Reduced 8.17%	41,701 $11.5 Million
Q4 2020 Feb 12, 2021	BUY	$248.13 - $308.36 $454,326 - $564,607	1,831 Added 4.2%	45,413 $13.4 Million
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $88,574 - $112,001	-411 Reduced 0.93%	43,582 $11.4 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $327,011 - $597,159	-2,566 Reduced 5.51%	43,993 $9.91 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $1.36 Million - $2.07 Million	-12,525 Reduced 21.2%	46,559 $6.13 Million
Q4 2019 Feb 18, 2020	SELL	$106.59 - $164.21 $2.23 Million - $3.43 Million	-20,880 Reduced 26.11%	59,084 $9.48 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $13,483 - $17,910	-119 Reduced 0.15%	79,964 $9.11 Million
Q2 2019 Aug 13, 2019	SELL	$115.0 - $141.58 $3.2 Million - $3.94 Million	-27,823 Reduced 25.78%	80,083 $11.3 Million
Q2 2018 Aug 13, 2018	SELL	$74.84 - $100.16 $2.85 Million - $3.82 Million	-38,112 Reduced 26.1%	107,906 $8.94 Million
Q1 2018 May 14, 2018	SELL	$56.95 - $85.19 $1.66 Million - $2.49 Million	-29,227 Reduced 16.68%	146,018 $11.7 Million
Q4 2017 Feb 13, 2018	BUY	$22.57 - $63.56 $567,161 - $1.6 Million	25,129 Added 16.74%	175,245 $11.1 Million
Q3 2017 Nov 13, 2017	BUY	$19.81 - $22.61 $2.97 Million - $3.39 Million	150,116	150,116 $3.39 Million

Others Institutions Holding ARGX

# of Institutions

401

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account